Consider Buying Potential Takeover Target Altimmune [Seeking Alpha]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Seeking Alpha
Follow Play 8min Summary Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide. Jose Luis Pelaez Inc In light of the possible, significant superiority of Altimmune, Inc.'s NASDAQ: ALT ) weight loss drug in multiple, important areas, the company is likely to become a takeover target in the medium-to-long term. What's more, since a high proportion of the company's shares are being sold short, there's a significant chance of the shares undergoing a short-covering rally if news of the firm holding talks about a potential takeover surfaces. Given these points, I believe that ALT stock is significantly undervalued and
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune Added to Nasdaq Biotechnology IndexGlobeNewswire
- Altimmune Stock Up More Than 25% in a Month: Here's Why [Yahoo! Finance]Yahoo! Finance
- Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders [Yahoo! Finance]Yahoo! Finance
- Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting DisordersGlobeNewswire
- Altimmune to Participate at Two Upcoming Investor ConferencesGlobeNewswire
ALT
Earnings
- 11/12/24 - Beat
ALT
Sec Filings
- 12/11/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- ALT's page on the SEC website